Congress Asset Management Co. Sells 2,164 Shares of Zoetis Inc. $ZTS

Key Points

• Congress Asset Management Co. reduced its stake in Zoetis Inc. by 1.2%, selling 2,164 shares during the second quarter, resulting in holdings worth $27,065,000.
• Analysts have issued mixed ratings on Zoetis, with price targets ranging from $155.00 to $215.00 and a consensus rating of "Moderate Buy."
• Zoetis reported a Q2 EPS of $1.76, exceeding expectations, and has set FY 2025 guidance of 6.300-6.400 EPS.

Congress Asset Management Co. lessened its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 1.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 173,551 shares of the company's stock after selling 2,164 shares during the period. Congress Asset Management Co.'s holdings in Zoetis were worth $27,065,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new stake in Zoetis during the second quarter valued at about $2,074,000. Perigon Wealth Management LLC grew its holdings in Zoetis by 0.5% during the second quarter. Perigon Wealth Management LLC now owns 24,201 shares of the company's stock valued at $3,774,000 after purchasing an additional 114 shares during the period. Castleview Partners LLC grew its holdings in Zoetis by 2.7% during the second quarter. Castleview Partners LLC now owns 3,865 shares of the company's stock valued at $603,000 after purchasing an additional 100 shares during the period. Sylvest Advisors LLC bought a new stake in Zoetis during the second quarter valued at about $813,000. Finally, Retirement Guys Formula LLC grew its holdings in Zoetis by 10.9% during the second quarter. Retirement Guys Formula LLC now owns 6,180 shares of the company's stock valued at $964,000 after purchasing an additional 606 shares during the period. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. Leerink Partners lowered Zoetis from an "outperform" rating to a "market perform" rating and cut their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Argus reaffirmed a "buy" rating and issued a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research note on Monday, August 11th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Leerink Partnrs lowered Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Five analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $200.88.

Zoetis Price Performance

Shares of Zoetis stock opened at $143.52 on Friday. The stock has a 50 day moving average of $150.35 and a 200 day moving average of $155.72. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $197.51. The firm has a market cap of $63.61 billion, a PE ratio of 24.70, a PEG ratio of 2.27 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.41 billion. During the same period in the prior year, the company earned $1.56 earnings per share. The firm's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.